Fanconi anemia complementation group D1
MONDO:0011584Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations is a rare cancer-predisposing syndrome, associated with the D1 subgroup of Fanconi anemia (FA), characterized by progressive bone marrow failure, cardiac, brain, intestinal or skeletal abnormalities and predisposition to various malignancies. Bone marrow suppression and the incidence of developmental abnormalities are less frequent than in other FA, but cancer risk is very high with the spectrum of childhood cancers including Wilms tumor, brain tumor (often medulloblastoma) and ALL/AML.
Also known as: FAD1, FANCD1, Fanconi anemia complementation group D1, Fad1, Fanconi anemia, complementation group D1, inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
18 clinical trials for this condition and its sub-types, 6 tagged with Fanconi anemia complementation group D1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Which drug first? trial tests sequence of carboplatin and olaparib in aggressive prostate cancer
Disease control Recruiting nowResearchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC